Literature DB >> 12963043

Blocking the dengue virus 2 infections on BHK-21 cells with purified recombinant dengue virus 2 E protein expressed in Escherichia coli.

Mei-Wui Chiu1, Yun-Liang Yang.   

Abstract

Dengue viruses (DVs) are mosquito-borne infectious pathogens. They have become an expanding public health problem in the tropics and subtropics. The dengue envelope (E) protein is one of the viral structure proteins responsible mainly for the virus attachment and entry onto host cells. It is also the major immunogen for virus neutralization. In this study, we have constructed a recombinant plasmid expressing a truncated E protein of DV-2 virus PL046 strain. The C-terminal hydrophobic domain of the E protein was removed and replaced with the sequence of S peptide to facilitate expression and purification. When expressed in Escherichia coli, the recombinant E proteins were found to be in the form of aggregated state. Through denaturation and dialysis processes, the receptor-interacting function of the purified recombinant E proteins was maintained, which was demonstrated by its ability to inhibit the DV-2 plaque-forming efficiency on mammalian BHK-21 host cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12963043     DOI: 10.1016/j.bbrc.2003.08.053

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Dynamics and binding interactions of peptide inhibitors of dengue virus entry.

Authors:  Diyana Mohd Isa; Sek Peng Chin; Wei Lim Chong; Sharifuddin M Zain; Noorsaadah Abd Rahman; Vannajan Sanghiran Lee
Journal:  J Biol Phys       Date:  2019-01-24       Impact factor: 1.365

2.  Recombinant dengue virus-like particles from Pichia pastoris: efficient production and immunological properties.

Authors:  Wenquan Liu; Hanning Jiang; Junmei Zhou; Xiaomeng Yang; Yunxia Tang; Danyun Fang; Lifang Jiang
Journal:  Virus Genes       Date:  2009-11-03       Impact factor: 2.332

Review 3.  Degrees of maturity: the complex structure and biology of flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Curr Opin Virol       Date:  2012-03-23       Impact factor: 7.090

4.  Suppressive effect of dengue virus envelope protein domain III on megakaryopoiesis.

Authors:  Guan-Ling Lin; Hsin-Hou Chang; Te-Sheng Lien; Po-Kong Chen; Hao Chan; Mei-Tzu Su; Chi-Yuan Liao; Der-Shan Sun
Journal:  Virulence       Date:  2017-07-20       Impact factor: 5.882

Review 5.  Focus on flaviviruses: current and future drug targets.

Authors:  Brian J Geiss; Hillary Stahla; Amanda M Hannah; Amanda M Gari; Susan M Keenan
Journal:  Future Med Chem       Date:  2009-05       Impact factor: 3.808

6.  Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.

Authors:  Yan Liu; Junmei Zhou; Zhizhun Yu; Danyun Fang; Chunyun Fu; Xun Zhu; Zhenjian He; Huijun Yan; Lifang Jiang
Journal:  BMC Microbiol       Date:  2014-12-18       Impact factor: 3.605

7.  Phage-Displayed Peptides Selected to Bind Envelope Glycoprotein Show Antiviral Activity against Dengue Virus Serotype 2.

Authors:  Carolina de la Guardia; Mario Quijada; Ricardo Lleonart
Journal:  Adv Virol       Date:  2017-09-10

8.  Investigating Tick-borne Flaviviral-like Particles as a Delivery System for Gene Therapy.

Authors:  Anne H Neddermeyer; Kjell Hultenby; Maruthibabu Paidikondala; Ryan M Schuchman; Mehdi R M Bidokhti
Journal:  Curr Ther Res Clin Exp       Date:  2017-10-16

9.  Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors.

Authors:  Jinn-Moon Yang; Yan-Fu Chen; Yu-Yin Tu; Kuei-Rong Yen; Yun-Liang Yang
Journal:  PLoS One       Date:  2007-05-09       Impact factor: 3.240

10.  Proteomic identification of dengue virus binding proteins in Aedes aegypti mosquitoes and Aedes albopictus cells.

Authors:  Maria de Lourdes Muñoz; Gustavo Limón-Camacho; Rosalinda Tovar; Alvaro Diaz-Badillo; Guillermo Mendoza-Hernández; William C Black
Journal:  Biomed Res Int       Date:  2013-11-10       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.